A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Phase of Trial: Phase II/III
Latest Information Update: 22 Jan 2019
At a glance
- Drugs Omburtamab-I-131 (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- Sponsors Y-mAbs Therapeutics
- 30 Oct 2018 Status changed from not yet recruiting to recruiting.
- 02 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.
- 28 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.